SUMMARY The effect of ivermectin, a new microfilaricide, was assessed in a double blind trial against diethylcarbamazine citrate (DEC) and placebo. Fifty-nine adult males with moderate to heavy infection with Onchocerca volvulus and with eye involvement were recruited from an area under Onchocerciasis Control Programme (OCP) vector control in Northern Ghana. They were randomly assigned to an eight-day treatment with ivermectin as a single dose of 12 mg on day 1 followed by placebo for the remaining seven days, or DEC, total dose 1-3 g, or placebo, and ophthalmological review was undertaken over a period of one year. DEC acted quickly to eliminate microflariae from the eye and was associated with reactive ocular changes and in a few cases functional deficit. Ivermectin eliminated microfilariae slowly from the anterior chamber of the eye over a period of six months. The ocular inflammatory reaction was minimal and no functional deficit occurred. It is postulated that the observed slow action of ivermectin on the eye may be attributed in part to its inability to cross the blood-aqueous humour barrier because of its molecular size as a macrocyclic lactone causing microfilariae to leave the eye gradually along a newly created gradient. Ivermectin is an effective microfilaricide with minimal ocular adverse effect and could therefore be suitable for widespread application without strict supervision.
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The effect of ivermectin, a new microfilaricide, was assessed in a double blind trial against diethylcarbamazine citrate (DEC) and placebo. Fifty-nine adult males with moderate to heavy infection with Onchocerca volvulus and with eye involvement were recruited from an area under Onchocerciasis Control Programme (OCP) vector control in Northern Ghana. They were randomly assigned to an eight-day treatment with ivermectin as a single dose of 12 mg on day 1 followed by placebo for the remaining seven days, or DEC, total dose 1-3 g, or placebo, and ophthalmological review was undertaken over a period of one year. DEC acted quickly to eliminate microflariae from the eye and was associated with reactive ocular changes and in a few cases functional deficit. Ivermectin eliminated microfilariae slowly from the anterior chamber of the eye over a period of six months. The ocular inflammatory reaction was minimal and no functional deficit occurred. It is postulated that the observed slow action of ivermectin on the eye may be attributed in part to its inability to cross the blood-aqueous humour barrier because of its molecular size as a macrocyclic lactone causing microfilariae to leave the eye gradually along a newly created gradient. Ivermectin is an effective microfilaricide with minimal ocular adverse effect and could therefore be suitable for widespread application without strict supervision. Diethylcarbamazine Ophthalmological examination. This was undertaken before treatment began and on the 2nd, 4th, 8th, 14th, and 28th days and 3, 6, and 12 months after the start of treatment. This included a visual acuity test using the illiterate E chart at 6 m distance for each eye separately and without correction for refractive error as well as a visual field test using 1 m Bjerrum tangent screen with a 2 mm white target in daylight at 1 metre distance. Slit-lamp examination was conducted after head down positioning of patients for at least two minutes to facilitate and standardise counting of microfilariae in the anterior chamber. Microfilariae, both dead and alive, and onchocercal punctate keratitis in the cornea were counted. The intraocular pressure was measured after the examination of the anterior segment of the eye was completed. The fundus was examined by both direct and indirect ophthalmoscopy after pupil dilatation. Fundus photography and fluorescein angiography were undertaken with a Topcon TRC fundus camera initially and later a Kowa RC2.
Drug administration. Twenty patients received DEC in a dose of 50 mg each morning for two days and then 100 mg twice daily for a further six days; 20 received ivermectin in a single dose of 12 mg on the morning of the first day and placebo capsules thereafter; and 19 received matching placebo capsules containing 185 mg corn starch (STA-RX L500) per capsule for the duration of therapy. The drugs, which were formulated in identical capsules and precoded, were allocated randomly to patients on arrival in the hospital. An elaborate check system was conducted to ensure correct drug administration and complete ingestion.
Statistical analysis. Non-parametric significance tests have been applied. The Kruskal-Wallis one-way ANOVA was used to compare all three treatment groups and the Mann-Whitney U test to compare the two treatment groups on each examination day. Within each group the post-treatment data were compared with baseline data by the Wilcoxon matched pairs, signed-ranks test. The study code was broken after the six months follow-up examination. RESPONSE TO TREATMENT General Systemic reactions. Headache, joint pains, muscle aches, and cardiovascular reactions were found with equal overall severity in both treatment groups. However, itching, node pain and tenderness, tachypnoea, and rash were more severe in DEC than in ivermectin treated patients. Fever was more prominent with ivermectin treatment than with DEC. Acute febrile polyarthritis involving the knees, ankles, elbows, and small joints of the hands and feet, which occurs classically several days after initiation of therapy, was observed in five patients treated with DEC but in none-of those treated with ivermectin.
Skin microfilariae. Both DEC and ivermectin treated groups showed a similarly significant decrease in the mean microfilarial density compared with the placebo treated group, with the lowest mean level of 1.3 microfilariae per mg of skin at day 8 for DEC and 0-9 at day 14 and 28 for ivermectin. Both groups showed a slight rise at six months, but at 9 and 12 months the DEC treated group had reached a significantly higher level than the ivermectin group. Adult worm. No macrofilaricidal effect was observed on adult worms removed at both one and six months with either DEC or ivermectin. A remarkably high number of degenerate microfilariae were seen in gravid worms taken at six months from patients treated with ivermectin. Ocular Changes in ocular parasite load. DEC caused rapid elimination of microfilariae from the anterior chamber, reaching near zero level by day 8, and remaining at this level with only minor fluctuation over the period of one year (Fig. 2) . This reduction, compared with that in the placebo treated group, is Both the DEC and ivermnectin groups increased from the baseline corneal microfilarial count to a peak on day 4; the increase caused by DEC was significant on days 2, 4, and 8 (p<0-01) (Fig. 3) . Compared with placebo, both DEC and ivermectin increased the corneal microfilarial load significantly on day 4 (p<0-05). Increase in onchoceral punctate keratitis occurred mainly with DEC and was significant on days 4 (p<0-01), 8 (Table 4 ). An increase in fluffy corneal opacities was seen only in patients treated with DEC (Fig. 4) Fundus changes. Four patients with optic disc changes were observed with fluorescein angiography, of whom two had received DEC treatment. One of these showed increasing disc hyperfluorescence from day 2 to 28 and fresh pigment epithelial lesions.' This patient lost fields bilaterally and progressively from day 4, to stabilise as bilateral contracted fields by day 14. The other patient showed an increasing disc hyperfluorescence from day 2 to 8 without pigment epithelial change but with accompanying left eye field loss on day 2, followed by the right on day 4, and progressing gradually until day 28. The two other Table 4 Comparison ofinflammatorysigns 
Discussion
The effect of a microfilaricide may be observed and quantified by observing the death or the elimination of microfilariae from the anterior segment of the eye and the tissue reaction to dead microfilariae.
In this study the evidence for the elimination of microfilariae from the anterior segment of the eye by both DEC and ivermectin is demonstrated. Despite the low counts of corneal microfilariae initially, which is a normal finding in patients in an area under vector control," the mobilisation of microfilariae into the cornea'2 during the first week of treatment occurred in both the DEC and ivermectin treated groups, the effect with DEC being the greater. However, only DEC caused a significant increase in onchocercal punctate keratitis. This phenomenon has also been observed in similar trials.22 I As in our previous open study,'2 the most striking finding was the mobilisation of microfilariae into the anterior chamber by ivermectin to a peak on day 4 which was a significant increase from baseline, followed by elimination to zero level by six months, while DEC promptly eliminated microfilariae to near zero level by day 8.
Although it is believed that the antiparasitic effect of ivermectin may result from its action in the mediation of neurotransmission by y-aminobutyric acid,27 and although ivermectin has been shown to kill Onchocera lienalis in vitro,' the precise mode of action of ivermectin in human ocular onchocerciasis is unknown, and several factors may have a contributory role. As a macrocyclic lactone, it is possible that ivermectin cannot cross the blood-aqueous humour barrier to enter the anterior chamber of the eye and exert direct action on the microfilariae. Ivermectin may conceivably act by eliminating the source of microfilariae migrating into the eye from surrounding skin and orbital tissue, thus reversing the microfilarial concentration gradient. Microfilariae may then leave the anterior chamber along this gradient, possibly along the same route by which they entered, or they might die naturally. This lack of microfilaricidal effect of ivermectin in the eye might account for the paucity of ocular inflammatory reaction. By contrast, DEC has been shown to enter the anterior chamber of the eye in therapeutic concentrations. 29 The postulated actions of the two drugs may explain the difference in time taken to eliminate microfilariae from the anterior chamber of the eye as well as differences in ocular tissue reaction in the form of inflammation. Limbitis, which can be used to quantify the severity of host reaction to a microfilaricide,32 occurred in the majority of patients treated with DEC but rarely in those treated with ivermectin. DEC caused optic nerve and pigment epithelial changes with functional deficit; although ivermectin caused papillitis, this was mild and was not associated with any defect in function. In similar studies 24 no changes at the posterior segment of the eye were observed in ivermectin treated patients.
Although the incidence of eye changes associated with DEC treatment in this study is quite considerable, it is still less than that reported by Bird et al. 7 in their study of 21 patients who were observed for two weeks in southern Sudan. Factors that may contribute to this difference may be: (1) the intensity of infection of the patients, which is lower in this study; (2) possible differences in the pattern of disease in the two different subregions; and (3) the possibility of changing host reaction in association with the interruption of transmission of infection. The absence of transmission of infection has been shown to lead to a decrease in the microfilarial load in the eye,' and this is reflected in the decreased microfilarial load of the anterior chambers and the resolution of papillitis in the placebo group after one year, as diagnosed by fluorescein angiography. This double blind study in patients living in an area subject to OCP vector control shows that ivermectin exerts a slow microfilaricidal effect on the eye, but, unlike DEC, does not produce any serious inflammatory reaction likely to cause functional deficit. These observations accord with those of our previous study.?2 In the light of similar conclusions drawn from studies undertaken where transmission of 0. volvulus continues unabated23 24 
